~ $4M

in Grants

Preclinical Success

Multiple CNS Indications

10 +

Patents / Publications

Independent Validation

First-in-class nanotherapeutics for neurological disorderss

Our nanotherapeutics selectively block extrasynaptic NMDA receptors—the drivers of pathological signaling—while preserving synaptic receptors essential for cognition, memory, and healthy brain function.

By restoring this balance, we aim to make the brain work better.

Yet current therapies are limited and have unacceptable side effects.

NMDA receptors (NMDARs) are validated targets in drug discovery. However, decades of clinical trials with NMDAR antagonists have failed because drugs indiscriminately block both synaptic (“good”) receptors required for normal brain function and extrasynaptic (“bad”) receptors that drive pathology.

The result: the therapeutic benefit of existing NMDAR antagonists is outweighed by cognitive impairment, dizziness, or worsening neurological function.

This selectivity problem has been deemed ‘insurmountable.’